KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Receivables - Other: 2017-2025

Historic Receivables - Other for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $2.3 million.

  • Aquestive Therapeutics' Receivables - Other rose 16.37% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 16.37%. This contributed to the annual value of $2.5 million for FY2024, which is 15.16% down from last year.
  • Per Aquestive Therapeutics' latest filing, its Receivables - Other stood at $2.3 million for Q3 2025, which was up 5.16% from $2.2 million recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Receivables - Other high stood at $6.0 million for Q4 2021, and its period low was $1.6 million during Q1 2024.
  • Moreover, its 3-year median value for Receivables - Other was $2.2 million (2025), whereas its average is $2.3 million.
  • In the last 5 years, Aquestive Therapeutics' Receivables - Other slumped by 70.44% in 2021 and then surged by 92.38% in 2023.
  • Over the past 5 years, Aquestive Therapeutics' Receivables - Other (Quarterly) stood at $6.0 million in 2021, then slumped by 64.35% to $2.1 million in 2022, then soared by 36.28% to $2.9 million in 2023, then decreased by 15.16% to $2.5 million in 2024, then rose by 16.37% to $2.3 million in 2025.
  • Its Receivables - Other stands at $2.3 million for Q3 2025, versus $2.2 million for Q2 2025 and $2.2 million for Q1 2025.